Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients

Nature Communications

Volumn 5, Issue , 2014, Pages

  Cho, Michael Jeffrey ^a   Lo, Agnes S Y ^b   Mao, Xuming ^a   Nagler, Arielle R ^a   Ellebrecht, Christoph T ^a   Mukherjee, Eric M ^a   Hammers, Christoph M ^a   Choi, Eun Jung ^a   Sharma, Preety M ^a   Uduman, Mohamed ^c   Li, Hong ^a   Rux, Ann H ^a   Farber, Sara A ^a   Rubin, Courtney B ^a   Kleinstein, Steven H ^c   Sachais, Bruce S ^a   Posner, Marshall R ^d   Cavacini, Lisa A ^d   Payne, Aimee S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AUTOANTIBODY; DESMOGLEIN 3 ANTIBODY; MONOCLONAL ANTIBODY; COMPLEMENTARITY DETERMINING REGION; DESMOGLEIN 3; DSG3 PROTEIN, HUMAN;

AMINO ACID; ANTIBODY; DISEASE PREVALENCE; GENE EXPRESSION; IMMUNE RESPONSE; MUTAGENICITY; MUTATION;

ARTICLE; CASE REPORT; CLONE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; GENE; GENE MUTATION; GENE SEQUENCE; HEAVY CHAIN; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; PATHOGENICITY; PEMPHIGUS VULGARIS; PHENOTYPE; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; SOMATIC MUTATION; VDJ RECOMBINATION; VH1 46 GENE; GENETICS; IMMUNOLOGY; PEMPHIGUS;

AUTOANTIBODIES; COMPLEMENTARITY DETERMINING REGIONS; DESMOGLEIN 3; HUMANS; IMMUNITY, HUMORAL; PEMPHIGUS;

EID: 84903121999     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5167     Document Type: Article

References (56)

1. Amagai, M., Karpati, S., Prussick, R., Klaus-Kovtun, V. & Stanley, J. R. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J. Clin. Invest. 90, 919-926 (1992).
2. Amagai, M., Hashimoto, T., Shimizu, N. & Nishikawa, T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J. Clin. Invest. 94, 59-67 (1994). (Pubitemid 24218077)
3. Anhalt, G. J. et al. Defining the role of complement in experimental pemphigus vulgaris in mice. J. Immunol. 137, 2835-2840 (1986). (Pubitemid 17177787)
4. Mascaro, Jr J. M. et al. Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence. Clin. Immunol. Immunopathol. 85, 90-96 (1997). (Pubitemid 27432007)
5. Mahoney, M. G. et al. Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J. Clin. Invest. 103, 461-468 (1999). (Pubitemid 29094045)
6. Shirakata, Y., Amagai, M., Hanakawa, Y., Nishikawa, T. & Hashimoto, K. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J. Invest. Dermatol. 110, 76-78 (1998). (Pubitemid 28086068)
7. Ishii, K. et al. Characterization of autoantibodies in pemphigus using antigenspecific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J. Immunol. 159, 2010-2017 (1997). (Pubitemid 127484192)
8. Ding, X. et al. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J. Invest. Dermatol. 109, 592-596 (1997). (Pubitemid 27433607)
9. Hanakawa, Y., Matsuyoshi, N. & Stanley, J. R. Expression of desmoglein 1 compensates for genetic loss of desmoglein 3 in keratinocyte adhesion. J. Invest. Dermatol. 119, 27-31 (2002). (Pubitemid 35304386)
10. Di Zenzo, G. et al. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J. Clin. Invest. 122, 3781-3790 (2012).
11. Boggon, T. J. et al. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 296, 1308-1313 (2002). (Pubitemid 34522784)
12. Al-Amoudi, A., Diez, D. C., Betts, M. J. & Frangakis, A. S. The molecular architecture of cadherins in native epidermal desmosomes. Nature 450, 832-837 (2007). (Pubitemid 350231314)
13. Sarig, O. et al. Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. J. Invest. Dermatol. 132, 1798-1805 (2012).
14. Sinha, A. A. et al. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 239, 1026-1029 (1988). (Pubitemid 18094171)
15. Ahmed, A. R. et al. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc. Natl Acad. Sci. USA 87, 7685-7662 (1990).
16. Veldman, C. M. et al. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J. Immunol. 172, 3883-3892 (2004). (Pubitemid 38337976)
17. Veldman, C., Höhne, A., Dieckmann, D., Schuler, G. & Hertl, M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol. 172, 6468-6475 (2004). (Pubitemid 38621257)
18. Payne, A. S. et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J. Clin. Invest. 115, 888-899 (2005). (Pubitemid 40489393)
19. Qian, Y., Diaz, L. A., Ye, J. & Clarke, S. H. Dissecting the anti-desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients. J. Immunol. 178, 5982-5990 (2007). (Pubitemid 46674396)
20. Yeh, S. W. et al. Pathogenic human monoclonal antibody against desmoglein 3. Clin. Immunol. 120, 68-75 (2006).
21. Shlomchik, M. J., Marshak-Rothstein, A., Wolfowicz, C. B., Rothstein, T. L. & Weigert, M. G. The role of clonal selection and somatic mutation in autoimmunity. Nature 328, 805-811 (1987). (Pubitemid 17118532)
22. Yaari, G., Uduman, M. & Kleinstein, S. H. Quantifying selection in highthroughput immunoglobulin sequencing data sets. Nucleic Acids Res. 40, e134 (2012).
23. Yaari, G. et al. Models of somatic hypermutation targeting and substitution based on synonymous mutations from high-throughput immunoglobulin sequencing data. Front. Immunol. 4, 358 (2013).
24. Tsunoda, K. et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J. Immunol. 170, 2170-2178 (2003). (Pubitemid 36197441)
25. Tsunoda, K. et al. Pathogenic relevance of IgG and IgM antibodies against desmoglein 3 in blister formation in pemphigus vulgaris. Am. J. Pathol. 179, 795-806 (2011).
26. Saito, M. et al. Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation. PLoS ONE 7, e50696 (2012).
27. Marzari, R. et al. Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease. J. Immunol. 166, 4170-4176 (2001). (Pubitemid 32224950)
28. Di Niro, R. et al. High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat. Med. 18, 441-445 (2012).
29. Saleh, M. A. et al. Pathogenic anti-desmoglein 3 mAbs cloned from a paraneoplastic pemphigus patient by phage display. J. Invest. Dermatol. 132, 1141-1148 (2012).
30. Ishii, K., Lin, C. Y., Siegel, D. L. & Stanley, J. R. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J. Invest. Dermatol. 128, 939-948 (2008). (Pubitemid 351374311)
31. Yamagami, J. et al. Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol. 183, 5615-5621 (2009).
32. Wang, G. et al. Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. Am. J. Pathol. 176, 914-925 (2010).
33. Frances, V. et al. The human anti-bullous pemphigoid monoclonal autoantibody P22 is encoded by genes of the IGHV4 and IGLV4 families. J. Autoimmun. 15, 459-468 (2000).
34. Ohyama, B. et al. Epitope spreading is rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2-based swapped molecules. J. Invest. Dermatol. 132, 1158-1168 (2012).
35. Kawasaki, H. et al. Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J. Invest. Dermatol. 126, 2621-2630 (2006). (Pubitemid 44764046)
36. Amagai, M. et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br. J. Dermatol. 140, 351-357 (1999). (Pubitemid 29111371)
37. Mouquet, H. et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591-595 (2010).
38. Samuels, J., Ng, Y. S., Coupillaud, C., Paget, D. & Meffre, E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201, 1659-1667 (2005). (Pubitemid 40721009)
39. Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703-711 (2005). (Pubitemid 40395116)
40. Kinnunen, T. et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J. Clin. Invest. 123, 2737-2741 (2013).
41. Zhang, J. & Yeh, M. Cloning, sequencing and analyzing of the heavy chain V region genes of human polyreactive antibodies. Cell Res. 4, 31-46 (1994).
42. Yamagami, J. et al. Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. J. Clin. Invest. 120, 4111-4117 (2010).
43. Mouquet, H. et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J. Invest. Dermatol. 128, 2859-2869 (2008).
44. Nagel, A. et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J. Invest. Dermatol. 129, 2202-2210 (2009).
45. Wada, N. et al. Aire-dependent thymic expression of desmoglein 3, the autoantigen in pemphigus vulgaris, and its role in T-cell tolerance. J. Invest. Dermatol. 131, 410-417 (2011).
46. Colliou, N. et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci. Transl. Med. 5, 175ra30 (2013).
47. Posner, M. R., Elboim, H. & Santos, D. The construction and use of a humanmouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 6, 611-625 (1987). (Pubitemid 18051305)
48. Liu, F. et al. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res. Hum. Retroviruses 19, 597-607 (2003). (Pubitemid 36903283)
49. Chang, T. Y. & Siegel, D. L. Genetic and immunological properties of phagedisplayed human anti-Rh(D) antibodies: implications for Rh(D) epitope topology. Blood 91, 3066-3078 (1998). (Pubitemid 28227561)
50. Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503-W508 (2008).
51. Giudicelli, V., Brochet, X. & Lefranc, M. P. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc. 2011, 695-715 (2011).
52. Volpe, J. M., Cowell, L. G. & Kepler, T. B. SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22, 438-444 (2006). (Pubitemid 43231418)
53. Barbas, C. F. I., Burton, D. R., Scott, J. K. & Silverman, G. J. Phage Display: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 2001).
54. Ishii, K. & Amagai, M. In vitro pathogenicity assay for anti-desmoglein autoantibodies in pemphigus. Methods Mol. Biol. 961, 219-225 (2013).
55. Futei, Y. et al. Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris. J. Invest. Dermatol. 115, 829-834 (2000).
56. Mao, X. et al. Autoimmunity to desmocollin 3 in pemphigus vulgaris. Am. J. Pathol. 177, 2724-2730 (2010).